FINHUB Insights

BSX · Q2 FY25 · Apr 1 – Jun 30, 2025

Boston Scientific Q2 FY25: where the revenue came from and where it went

Boston Scientific Q2 FY25: revenue $5.1B (+23% year over year). Net profit $0.8B. Largest cohort Electrophysiology EP $0.8B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 1, 2025 10-Q
Sankey diagram of Boston Scientific's income statement for Q2 FY25: revenue of $5.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.1B +23% year over year
Gross profit$3.4B 68% margin
Operating profit$0.8B 16% margin
Net profit$0.8B 16% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 5.1 100% +23%
Electrophysiology EP 0.8 16% +96%
Global Endoscopy Endo Reporting… 0.7 14% +9%
Interventional Cardiology… 0.7 14% +10%
Global Peripheral Interventions… 0.7 14% +18%
Global Urology and Pelvic Health… 0.7 14% +29%
Cardiac Rhythm Management 0.6 12% +2%
Watchman 0.5 10% +28%
Global Neuromodulation Nm… 0.3 6% +7%
Cost of revenue−1.631%
Gross profit3.468% margin−2pp
SG&A−1.734%−1pp
Other−0.918%+0pp
Operating profit0.816% margin+4pp
Tax−0.1
Net profit0.816%+8pp
Filing on EDGAR More quarters of BSX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters